PANASONIC-CORPORATION
16.3.2021 03:15:09 CET | Business Wire | Press release
Panasonic Corporation has begun licensing the HD-PLCTM 4*1 IP core required for the design of semiconductors with technologies and functions that comply with the IEEE 1901–2020*2 international standard. This IP core is the fourth generation of the HD-PLC series. Although conventionally HD-PLC have used power lines for transmission, this new series enables transmission through existing metal wires, such as control lines and coaxial cables as well as power lines, expanding its range of applications. This new HD-PLC technology also enables higher speeds, greater distance, and less wiring for wired communications.
By using this IP core, semiconductor and peripheral equipment manufacturers will be able to flexibly meet to a range of IoT service requirements and manufacture products that respond to these needs.
As a wide range of equipment in society becomes digitalized and connects to the IoT devices, communication technologies are becoming increasingly important. While the adoption of wireless technologies such as 5G and high-speed fiber optic internet gains pace, there are some locations in which it is difficult to access wireless communication. Here, the use of existing metal wires—in the walls and ceilings of buildings, underground facilities, and equipment—as communication mediums fulfils a vital role. This IP core is a solution that can rapidly meet to the requirements of the era of IoT, such as higher-speed networks, enhanced security, and internet protocol networks. By combining the IP core with wireless and other technologies, it can help create optimal networks in a range of environments, from living spaces to social infrastructure.
Using its experience and achievements with the HD-PLC 3 IP core, which is currently on the market, in addition to licensing of this new IP core, Panasonic will provide one-stop development support to users which will include proposals for analog front-end circuitry—key to the mounting of semiconductors. Further, as a high-speed wired communication solution, Panasonic will seek to use this technology to expand the adoption of IoT PLC, ultimately applying the technology to large-scale networks that cover living spaces, buildings, factories, smart cities, and other social infrastructure.
This IP core is first licensed to Socionext Inc. This enables the supply of higher performance semiconductors with lower energy consumption using fourth generation HD-PLC. It is expected that these will then be built-in to a range of IoT-connected devices.
Panasonic launched a dedicated website with more information about this technology. Please note that the global IEEE SA and HD-PLC Alliance*3 Webinar will be held on March 18, 2021.
Main Features
- The standard mode communication band (250 Mbps) can be doubled or quadrupled, allowing a 500 Mbps*4 communication speed in double mode or a maximum of 1 Gbps*4 in quadruple mode on coaxial cable or dedicated line.
- The standard mode communication band can be compressed on two levels (half or quarter), concentrating and extending the communication distance up to twice*5 the distance in standard mode.
- With the multi-hop function, it is possible to operate a wide area network of up to 1024 nodes.
Main Specifications
Communication
|
High-speed mode (1 Gbps, 500 Mbps) *Optional Standard mode (250 Mbps) Long-distance mode (2 x or 1.5 x the range of standard mode) |
Approved
|
IEEE 1901-2020 ITU-T G.9972 (Coexistence mechanism for different PLC systems) ITU-T G.9905 (Multi-hop) *Optional EN 50561-1:2013 (Dynamic notch and dynamic power control) |
Inquiries Regarding IP Core Licensing
IoT PLC Project Help Desk
Email: hd-plc_press@ml.jp.panasonic.com
Website: https://www.panasonic.com/global/business/hd-plc/en.html
*1: HD-PLCTM
is the name of the high-speed power line communications system proposed by Panasonic Corporation, and is a trademark or registered trademark of Panasonic Corporation in Japan and other countries. HD-PLCTM
4 is the name of the fourth-generation semiconductor IP core.
*2: Formulated by the IEEE Standards Association (a communication standards subsidiary of the Institute of Electrical and Electronics Engineers) on January 19, 2021, this is a standard for technologies with higher speeds and longer distances than those outlined in IEEE 1901-2010.
IEEE 1901-2020 - IEEE Standard for Broadband over Power Line Networks: Medium Access Control and Physical Layer Specifications: https://standards.ieee.org/standard/1901-2020.html
*3: An alliance formed on September 25, 2007, to support, promote and implement the HD-PLC system for High-Speed Power Line Communications and to ensure mutual compatibility.
Website: https://hd-plc.org/
*4: 500 Mbps and 1 Gbps are theoretical speeds at the physical layer.
*5: Maximum distance may change depending on communication environment.
About Panasonic
Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 528 subsidiaries and 72 associated companies worldwide, recording consolidated net sales of 7.49 trillion yen for the year ended March 31, 2020. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global
.
Source: https://news.panasonic.com/global/press/data/2021/03/en210316-2/en210316-2.html
Related Links
IEEE SA and HD-PLC Alliance Webinar March 2021: Home Networking, Industrial and Building Automation through HD-PLC (High Speed Powerline Communication)
https://standards.ieee.org/events/index.html
[Press Release] Panasonic's Next-generation HD-PLC®
, BPL Communication Technology Adopted as IEEE 1901a Standard
https://news.panasonic.com/global/press/data/2019/03/en190325-4/en190325-4.html
Socionext Inc. related press release
https://www.socionext.com/en/pr/sn_pr20210309_01e.pdf
HD-PLC Alliance
https://hd-plc.org/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005858/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
